Phase 3 trial to evaluate the safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by 23-valent pneumococcal polysaccharide vaccine 6 months later, in at-risk adults 18-49 years of age (PNEU-DAY): A subgroup analysis by baseline risk factors.
Saved in:
| Title: | Phase 3 trial to evaluate the safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by 23-valent pneumococcal polysaccharide vaccine 6 months later, in at-risk adults 18-49 years of age (PNEU-DAY): A subgroup analysis by baseline risk factors. |
|---|---|
| Authors: | Hammitt LL; International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA., Quinn D; P3 Research, Wellington Clinical Trial Research Unit, Wellington, New Zealand., Janczewska E; The School of Health Sciences in Bytom, Medical University of Silesia, Bytom, Poland., Pasquel FJ; Division of Endocrinology, Metabolism, and Lipids, Department of Medicine, Emory University School of Medicine, Atlanta, GA, USA., Tytus R; Family Medicine, McMaster University, Ontario, Canada., Reddy KR; Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA., Abarca K; Escuela de Medicina, Pontificia Universidad Catolica de Chile, Santiago, Chile., Khaertynova IM; Department of Infectious Diseases, Kazan State Medical Academy, Kazan, Russia., Dagan R; The Shraga Segal Department of Microbiology, Immunology and Genetics, Faculty of Health Sciences of the Ben-Gurion University of the Negev, Beer-Sheva, Israel., Dawson R; Merck & Co., Inc., Rahway, NJ, USA., McCauley J; Merck & Co., Inc., Rahway, NJ, USA., Shekar T; Merck & Co., Inc., Rahway, NJ, USA., Fu W; Merck & Co., Inc., Rahway, NJ, USA., Pedley A; Merck & Co., Inc., Rahway, NJ, USA., Sterling T; Merck & Co., Inc., Rahway, NJ, USA., Tamms G; Merck & Co., Inc., Rahway, NJ, USA., Musey L; Merck & Co., Inc., Rahway, NJ, USA., Buchwald UK; Merck & Co., Inc., Rahway, NJ, USA. |
| Source: | Human vaccines & immunotherapeutics [Hum Vaccin Immunother] 2023 Dec 31; Vol. 19 (1), pp. 2177066. Date of Electronic Publication: 2023 Mar 02. |
| Publication Type: | Clinical Trial, Phase III; Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Taylor & Francis Country of Publication: United States NLM ID: 101572652 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2164-554X (Electronic) Linking ISSN: 21645515 NLM ISO Abbreviation: Hum Vaccin Immunother Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
